name: (2R,3S,4R,5R)-2,3,4,5-Tetrahydroxy-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexanal. In homogeneous catalysis, catalysts are in the same phase as the reactants. Enzymes are biological catalysts that produce large increases in reaction rates and tend to be specific for certain reactants and products. Introducing a new discovery about 499-40-1, Name is (2R,3S,4R,5R)-2,3,4,5-Tetrahydroxy-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexanal
New copper(II) ternary complexes formulated as [Cu(N-N)BIG]ClO4, where BIG is deprotonated 2-((1H-benzimidazol-2-yl)methylamino)acetic acid and N-N represents 2,2?-bipyridine (1) or 4,4?-dimethyl-2,2?-bipyridine (2) or 5,5?-dimethyl-2,2?-bipyridine (3) or 1,10-phenanthroline (4) or 4,5-diazafluoren-9-one (5) or dipyridylamine (6), were synthesized and characterized using analytical and spectral methods. Complex 1 was characterized using single-crystal X-ray diffraction analysis and found to be monomeric in nature with distorted square pyramidal geometry. The binding interactions of 1?6 with calf thymus DNA were studied using UV?visible absorption and emission spectroscopy and viscosity measurements. The DNA cleavage ability of 1?6 with pUC19 DNA shows that the complexes can cleave DNA without any external agents. The ligand and complexes were investigated for their in vitro antibacterial activity against Bacillus subtilis and Staphylococcus aureus. The complexes showed enhanced antibacterial activities compared to the free ligand. Molecular docking studies of complexes 1?6 were made using Genetic Optimization of Ligand Docking (GOLD) software. The study indicated that LEU23, ASP25, ILE84, ASN144 and ARG87 of COX-2 were important for strong hydrogen bonding interaction with the complexes. Among the complexes, 2 showed the best docking result with COX-2. Cytotoxicity assay was performed using MTT reagent against human cervical cancer cells, human breast cancer cells and human lung cancer cells. The complexes were found to show moderate anticancer activity.
Sometimes chemists are able to propose two or more mechanisms that are consistent with the available data.name: (2R,3S,4R,5R)-2,3,4,5-Tetrahydroxy-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexanal, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 499-40-1, in my other articles.
Reference：
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics